SCHEMBL4186428

SCHEMBL4186428

Clc1cccnc1-c1ccc(-c2nc3ncc(N4CCOCC4)cc3[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.52
PRMT5 O14744 2/20 0.48
TBK1 Q9UHD2 3/20 0.44
CBFB Q13951 1/20 0.43
INSR P06213 2/20 0.42
ALK Q9UM73 2/20 0.42
CNR2 P34972 2/20 0.40
KIF11 P52732 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
DGAT1 O75907 1/20 0.39
SOAT1 P35610 1/20 0.39
KCNH2 Q12809 1/20 0.39
GUSB P08236 1/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CG P48736 1/20 0.38
GRM4 Q14833 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181928 0.92 AURKA (0.60) AURKAPRMT5TBK1CNR2KIF11
SCHEMBL4196064 0.84 CBFB (0.62) AURKACBFBSIRT2SIRT1DGAT1
SCHEMBL13945205 0.82 PARP1 (0.43) AURKACBFBCNR2SIRT2SIRT1
SCHEMBL16471238 0.78 AURKA (0.57) AURKAPRMT5KIF11GUSB
SCHEMBL4184277 0.77 CBFB (0.65) CBFBCNR2SIRT2SIRT1DGAT1
SCHEMBL4186703 0.75 AURKA (0.60) AURKACBFBKIF11DGAT1KCNH2
SCHEMBL4189704 0.75 DGAT1 (0.47) CBFBDGAT1SOAT1KCNH2
SCHEMBL4184280 0.73 CBFB (0.47) AURKACBFB
SCHEMBL4844138 0.71 TBK1 (0.61) AURKAPRMT5TBK1INSRALK
SCHEMBL4551767 0.71 SIRT2 (0.56) CBFBSIRT2SIRT1DGAT1SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US claimed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP claimed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US claimed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 AURKA 3834/4885PRMT5 4323/4885TBK1 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.